Aclaris Therapeutics

Entity > Corporation > US > New York City New York > Aclaris Therapeutics

About Aclaris Therapeutics

Aclaris Therapeutics, Inc. is a pharmaceutical company that deals in identifying, developing, and commercialization of drugs and therapies to meet needs in dermatology, medical, and immunology sectors. Aclaris Therapeutics serves patients in the United States.

KINect® is Aclaris Therapeutics’ Proprietary Drug Discovery Platform: Aclaris Therapeutics, Inc. has a multi-stage portfolio of drug candidates based on KINect®. The Company's drug candidates are Zunsemetinib (ATI -450), ATI -1777 and ATI -2138. ATI -450 is an orally administered, selective small molecule MK2 inhibitor for the treatment of rheumatoid arthritis. ATI -1777, a topical JAK 1/3 inhibitor for the treatment of atopic dermatitis. It is also developing ATI -2138 as a potential treatment for T cell-mediated autoimmune diseases. The company is also developing oral inhibitors of intestinal flora JAK as a potential treatment for inflammatory bowel disease.

Aclaris Operates in Two Segments: Aclaris Therapeutics, Inc. operates in two segments: Therapeutics and Contract Research. The Therapeutics segment is engaged in identifying and developing innovative therapies to address significant unmet needs in immune-inflammatory diseases. The Contract Research segment is active in the provision of laboratory services.

Aclaris Therapeutics, Inc. Was Founded in 2012: The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about Aclaris Therapeutics

Company Attribute Value
Address StreetAddress: 640 Lee Rd Ste 200, AddressLocality: Wayne, AddressRegion: Pennsylvania, PostalCode: 19087, AddressCountry: United States
Founding Date 2012
Name Aclaris Therapeutics
Number Of Employees 72
Revenue $6,437,000 USD
Ticker Symbol NASDAQ: ACRS
Url aclaristx
Facebook facebook
Linkedin linkedin
Twitter twitter
Google google
Wikidata wikidata

Aclaris Therapeutics


New York City, US
5 Jul 2024

New York City, US
5 Jul 2024

Aclaris Therapeutics

Page: 1 Desktop | Laptop Devices
Home | Aclaris Therapeutics Inc.
Aclaris is a biopharmaceutical company that strives to translate scientific discoveries into everyday victories in dermatology, and beyond. › quote › ACRS
Aclaris Therapeutics, Inc. (ACRS) Stock Price, News, Quote ...
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases ... › quotes › ACRS
ACRS: Aclaris Therapeutics Inc - Stock Price, Quote and ...
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. › employer › aclaris-therape...
Articles about Aclaris Therapeutics
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, announced top-line ... › Quotes
ACRS | Aclaris Therapeutics Inc. Stock Price & News
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel ... › biotech › aclaris-lays-4...
Aclaris lays off 46%, resurrects zunsemetinib for cancer
Dec 20, 2023 — Aclaris Therapeutics has decided to give its MK2 inhibitor zunsemetinib a second chance—unfortunately, almost half of the biotech's ...
Related Searches
Related Searches
Aclaris therapeutics news
Aclaris Therapeutics layoffs
Aclaris therapeutics products
Google My Business
Google My Business

Aclaris Therapeutics, Inc (Pharmaceutical company in Chesterbrook, Pennsylvania)
  • Located in : Chesterbrook Corporate Center
  • Address : 701 Lee Rd #103, Wayne, PA 19087
  • Phone : (484) 324-7933

All information on this page is taken from publicly available sources, and the analysis we provide is a representation of Google's search results for the entity and does not represent any opinion or judgement about the entity by Kalicube itself. If you disagree with this analysis, please contact us and cite this reference : 188914